Barinthus Biotherapeutics (NASDAQ:BRNS) Announces Earnings Results

Barinthus Biotherapeutics (NASDAQ:BRNS) posted its quarterly earnings results on Thursday. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.02, FiscalAI reports.

Barinthus Biotherapeutics Stock Performance

BRNS traded up $0.03 during mid-day trading on Friday, reaching $0.60. 34,881 shares of the stock were exchanged, compared to its average volume of 40,767. Barinthus Biotherapeutics has a 1 year low of $0.51 and a 1 year high of $1.83. The stock has a market capitalization of $24.47 million, a PE ratio of -0.58 and a beta of -0.39. The company has a 50 day moving average price of $0.64 and a two-hundred day moving average price of $0.64.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised shares of Barinthus Biotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 21st. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $4.00.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Barinthus Biotherapeutics stock. Baird Financial Group Inc. grew its position in shares of Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) by 108.2% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 192,461 shares of the company’s stock after buying an additional 100,000 shares during the quarter. Baird Financial Group Inc. owned 0.48% of Barinthus Biotherapeutics worth $179,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 25.20% of the company’s stock.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.